A. Pande

发表

Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.

P. Philip, A. Zhu, M. Borad, 2021, The lancet. Gastroenterology & hepatology.

Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study

J. Gibbs, C. Garrett, R. Iyer, 2009, British Journal of Cancer.

Epidermal Growth Factor Receptor-Directed Therapy in Esophageal Cancer

J. Black, C. LeVea, R. Iyer, 2008, Oncology.

Hypertension secondary to anti-angiogenic therapy: experience with bevacizumab.

M. Javle, A. Pande, J. Lombardo, 2007, Anticancer research.

Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement.

P. Philip, G. Abou-Alfa, R. Kelley, 2021 .

A phase I/II study of dovitinib (TKI258), a FGFR and VEGFR inhibitor, in patients (pts) with advanced or metastatic renal cell cancer: Phase I results.

M. Shi, Chia‐Chi Lin, B. Escudier, 2010 .

Impact of dosing regimen of custirsen, an antisense oligonucleotide, on safety, tolerability and cardiac repolarization in healthy subjects.

S. Willsie, O. Spiegelstein, L. Rabinovich‐Guilatt, 2015, British journal of clinical pharmacology.

TKI258 (dovitinib lactate) in metastatic renal cell carcinoma (mRCC) patients refractory to approved targeted therapies: A phase I/II dose finding and biomarker study.

J. Soria, M. Shi, B. Escudier, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bevacizumab (BV) induced hypertension (HT): A manageable toxicity.

M. Wong, R. Iyer, M. Javle, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pilot Study of Gefitinib, Oxaliplatin, and Radiotherapy for Esophageal Adenocarcinoma: Tissue Effect Predicts Clinical Response

H. Nava, G. Wilding, J. Black, 2008, American journal of clinical oncology.

Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial.

S. Roychowdhury, A. Lamarca, I. Borbath, 2020, Future oncology.

Concurrent Oxaliplatin, 5-Fluorouracil, and Radiotherapy in the Treatment of Locally Advanced Esophageal Carcinoma

H. Nava, M. Javle, Gary Y. Yang, 2007, Cancer journal.

Tivantinib (ARQ 197) versus placebo in patients (Pts) with hepatocellular carcinoma (HCC) who failed one systemic therapy: Results of a randomized controlled phase II trial (RCT).

A. Gasbarrini, C. Porta, A. Santoro, 2012 .

Surgical resection for pancreatic cancer: Correlates of margin positivity.

J. Gibbs, B. Kuvshinoff, M. Javle, 2006, Journal of Clinical Oncology.